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Copyright © 2005 by The American Asso-
ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2004.07.051Objective: Histone deacetylase inhibitors mediate a potent growth-inhibitory effect
in cancer cells through induction of cell-cycle arrest and apoptosis. Moreover, these
agents significantly induce transcriptional activation of nuclear factor B, as well as
p21 regulated by protein kinase C, and are thought to negatively influence the ability
of histone deacetylase inhibitor to effectively mediate apoptosis. This study aimed
to evaluate the effect of calphostin C (a protein kinase C inhibitor) on trichostatin
A (a histone deacetylase inhibitor)–mediated upregulation of nuclear factor B and
p21 promotor transcriptional activity, as well as induction of apoptosis in lung and
esophageal cancer cells.
Methods: Cultured lung and esophageal cancer cells were treated with calphostin
C and trichostatin A. Nuclear factor B transcriptional activity was quantitated
by using the nuclear factor B–luciferase assay. Transcription of p21 gene and
p21 protein levels was evaluated by using the p21 promoter–luciferase assay and
the p21 enzyme-linked immunoassay, respectively. Apoptosis was evaluated by
using the terminal deoxynucleotidyl transferase–mediated dUTP nick end label-
ing– based ApoBrdU assay. Levels of expression of nuclear factor B– depen-
dent antiapoptotic and proapoptotic proteins were evaluated by means of West-
ern blotting.
Results: Exposure of lung or esophageal cancer cells to trichostatin A resulted in a
dose- and cell-dependent 2-fold to greater than 20-fold increase of nuclear factor B
and p21 transcriptional activity. Treatment with trichostatin A and calphostin C led
to a 50% to 90% decrease of trichostatin A– mediated upregulation of nuclear factor
B and p21 activation. Inhibition of nuclear factor B activity resulted in significant
reduction (30% to99%) of trichostatin A– mediated activation of not only nuclear
factor B transcription but also p21 promotor activity. Importantly, 90% to 96% of
thoracic cancer cells under-went apoptosis after exposure to the combination of
trichostatin A plus calphostin C.
Conclusion: Inhibition of protein kinase C abrogates trichostatin A–mediated up-
regulation of nuclear factor B transcriptional activity and p21 expression that is
associated with profound induction of apoptosis in lung or esophageal cancer cells.
Protein kinase C might be a novel target for enhancing the efficacy of histone
deacetylase inhibitor in cancer therapy.
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TSPrimary cancer of the upper aerodigestive tractremains one of the most common malignanciesworldwide. Surgical resection remains the treat-ment of choice for early-stage cancers of thelung or esophagus. However, the majority ofpatients with these malignancies frequently
present with locally advanced disease or with systemic metas-
tases. They therefore require multimodality therapy consisting
of cytotoxic chemotherapeutics and external beam radiation as
the standard of care.1-4 Unfortunately, metastatic lung and
esophageal cancers are quite refractory to current optimal
treatment regimens, with a median survival of less than 12
months. These disappointing clinical results, in combination
with better understanding of the molecular basis of carcino-
genesis, provide a strong impetus for the development of
novel treatment methods. Molecular targeted therapeu-
tics, aimed at oncogenic pathways operational in cancer
but not normal cells, offer a novel approach to this
difficult problem.
Histone deacetylase (HDAC) inhibitors are pharmaco-
logic compounds of diverse chemical structures that in-
duce hyperacetylation of nuclear histones and mediate
potent anticancer activity. HDAC inhibitors are currently
in early-phase clinical trials to treat hematologic and
solid tumor malignancies.5 It is important to note, how-
ever, that the magnitude of HDAC inhibitor–mediated
induction of apoptosis is dependent on the drug concen-
trations, as well as the duration of drug exposure, and that
the effects of HDAC inhibition are not solely related to
alterations in histone acetylation.6-8 It has been shown
that treating cultured cancer cells with HDAC inhibitor in
vitro results in rapid and profound transcriptional upregu-
lation of p21 gene expression,6,9 as well as activation of
the nuclear factor B (NF-B) pathway.10 Robust expres-
sion of NF-B– dependent, antiapoptotic proteins, such
as the cIAPs and Bcl-XL, have also been documented.11
It is well described that induction of these genes impedes
the ability of HDAC inhibitor to mediate apoptosis in
cancer cells12-15 and that inhibition of either p21 expres-
sion or NF-B activation was associated with induction
of apoptosis of HDAC inhibitor–treated cells.9,16-18 Pre-
viously, Han and colleagues19 demonstrated that HDAC
inhibitor–associated upregulation of p21 gene expression
is mediated by protein kinase C (PKC), and more re-
cently, PKC is thought to be a key regulator of NF-B
transactivation.20
Previously, we have demonstrated that the cdk inhibitor
flavopiridol potentiates cytotoxicity mediated by the HDAC
inhibitor depsipeptide FK228 in a variety of thoracic ma-
lignancies in vitro. Furthermore, we have shown that fla-
vopiridol inhibits the induction of p21 by depsipeptide and
can profoundly potentiate the HDAC inhibitor–mediated
apoptosis.16 However, this study was undertaken to extend
54 The Journal of Thoracic and Cardiovascular Surgery ● Januathose observations by examining whether inhibition of PKC
signaling by calphostin C (CC) could potentiate the cyto-
toxicity mediated by the HDAC inhibitor trichostatin A
(TSA) in lung and esophageal cancer (EsC) cells. These
experiments were predicated on the hypothesis that inhibi-
tion of PKC activity in HDAC inhibitor–treated cells would
abrogate not only p21 gene activation but also NF-B
upregulation, thus leading to more pronounced HDAC
inhibitor–induced apoptosis.
Materials and Methods
Cells and Reagents
The EsC cells TE2 and TE12 and the non–small cell lung cancer
(NSCLC) cells H322 and H460 were maintained in RPMI-1640
culture medium supplemented with fetal calf serum (10% vol/
vol), streptomycin (100 g/mL), penicillin (100 U/mL), and
glutamine (2 mmol/L). Primary human dermal fibroblasts and
human umbilical vein endothelial cells were purchased from
Clonetics Corp (Walkerville, Md). TSA (Sigma, St Louis, Mo),
CC (Calbiochem, La Jolla, Calif), and the NF-B inhibitor
parthenolide (Alexis) were dissolved in dimethyl sulfoxide to
stock solutions of 500 mol/L or 1000 mol/L and stored at
20°C. The adenovirus vector expressing the super repressor
mutant IB (Adv-SR-IB) was kindly provided by Dr Albert S.
Baldwin (University of North Carolina at Chapel Hill, Chapel
Hill, NC).
Cell Proliferation Assay
Cultured cancer cells or primary normal cells were seeded onto
96-well microtiter plates at a density of 5  103/well. After an
overnight incubation, cells were treated with TSA (0.10-5.0
mol/L for 12 hours), after which they were either maintained in
normal media or treated with CC (0.5-2.0 mol/L) for 60 hours.
Cell viability at the end of the assays was quantitated with (4,5-
dimethylthiazo-2-yl)-2,5-diphenyl- tetrazolium bromide (MTT;
Sigma).
Determination of Apoptosis
Cancer cells seeded at 2  105 per well in 6-well plates were
treated with either TSA alone (0.5-5.0 mol/L for 12 or 24 hours)
or with the sequential combination of TSA (1.0 or 2.0 mol/L for
12 hours) followed by CC (1.0 mol/L for 36 hours). Treated cells
were harvested at 48 hours after the onset of drug treatment, fixed
in 1% paraformaldehyde and 70% ethanol, and assayed for apo-
ptosis by using the terminal deoxynucleotidytransferase-mediated
dUTP nick end labeling (TUNEL)–based ApoBrdU assay (BD
Pharmingen, Torrance, Calif), as per the protocol provided by the
manufacturer.
NF-B and p21 Promotor Transcriptional Activity
The transcriptional activity of NF-B and of the p21 promotor was
evaluated by transient transfection of reporter plasmids that con-
tain the luciferase gene under the control of a promotor with
multiple NF-B binding sites or the promotor of the wild-type p21
gene, respectively, into cells before drug treatments. Luciferase
activity of cell lysates is directly correlated with the transcriptional
activity of NF-B or p21 promotor.
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The human wild-type p21 promoter–luciferase fusion plasmid
WWP-Luc (kindly provided by B. Vogelstein, John Hopkins Uni-
versity, Baltimore, Md) and the NF-B–luciferase reporter plas-
mid NF-B–Luc (Invitrogen, Carlsbad, Calif) were amplified and
CsCl purified (Lofstrand Labs, Gaithersburg, Md) for transient
Figure 1. A, Growth-inhibitory effects of TSA on the NSC
viability was quantitated by means of MTT assay and ex
presented as means  SEM of 4 independent experimen
the G0/G1 or G2/M phases of the cell cycle. Cultured canc
or 5.0 mol/L TSA for 12 hours and then further cultured
12 hours after completion of drug treatment, and cell-cyc
and flow cytometry. Representative data of 3 independentransfection experiments.
The Journal of ThoracTransfection and Luciferase Assay
Cells were plated onto 24-well plates at a density of 8  104/well.
For transcription experiments, cells were transfected with 500 ng
of DNA per well of either the WWP-Luc or NF-B-Luc plasmid
by using Fugene transfection reagent (Promega, Madison, Wis).
Twenty-four hours after transfection of the reporter plasmids,
ells H322 and H460 and the EsC cells TE2 and TE12. Cell
sed as percentages of untreated control cells. Data are
, TSA dose-dependent induction of cell growth arrest at
lls were treated with normal media and either 0.1mol/L
A-free complete culture media. Cells were harvested at
alysis was performed by using propidium iodide staining
eriments that yielded similar results are shown.LC c
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activity of NF-B or p21 promotor was quantitated by measur-
ing the luciferase activity of cell lysates with the Luciferase
Assay kit (Promega), according to the manufacturer’s recom-
mendation, by using the Lumat LB 9507 lucinometer (EG&G
Berthold, Gaithersburg, Md).
Quantitation of p21 Protein
The levels of p21 proteins in cells treated with TSA, CC, or the
TSACC combination were measured by using the enzyme-
linked immunosorbent assay method (Oncogene Science, Boston,
Mass). Cellular p21 levels were normalized for protein content of
cell lysates and expressed as units per milligram of cellular protein.
Western Blotting
Cultured NSCLC or EsC cancer cells treated with TSA (0.1 and
1.0 mol/L  12 hours), CC (1.0 mol/L  12 hours), or
sequential TSA (12 hours) followed by CC (12 hours) were har-
vested in Laemmli buffer at 24 hours after the onset of drug
exposure. Cell lysates were immunoblotted by using the standard
Western blot technique with monoclonal antibodies for Bcl-XL
(Cell Signaling Technology, Beverly, Mass), cIAP-1 and cIAP-2
(R&D Systems, Minneapolis, Minn), Bax (Upstate Biotechnology,
Figure 2. Induction of apoptosis by TSA treatment of t
TE12. Cells were exposed to TSA (0.5-5.0 mol/L) for
determination of apoptosis with the TUNEL-based ApoB
 SEM of 4 independent experiments. #P  .004 to .0
groups. *P  .0079 to .013, analysis of variance with T
2, and 5 mol/L and TSA of 0.5 mol/L.Lake Placid, NY), and mcl-1 (Pharmingen, San Diego, Calif).
56 The Journal of Thoracic and Cardiovascular Surgery ● JanuaBlots were also probed for -actin (Oncogen Research Product,
Cambridge, Mass) to verify equal loadings of protein.
Data Analysis
Data are expressed as means  SD for at least 3 independent
experiments that yielded similar results. Statistical analysis was
performed with the GraphPad InStat software (GraphPad, San
Diego, Calif).
Results
Growth-Inhibitory Effect of TSA on NSCLC and EsC
Cells
Brief exposure of cultured lung and EsC cells to TSA
resulted in a dose-dependent inhibition of cell proliferation
that was most pronounced in TE2, TE12, and H322 cells but
not in H460 cells (Figure 1, A). TSA at low concentrations
(0.1-1.0 mol/L) mediated cell-cycle arrest at the G1/S
checkpoint (increase of cells in the G0/G1 phase and reduc-
tion of cells in the S phase). At higher concentrations (2.0
mol/L), TSA induced a profound perturbation of mitosis
that was associated with significant accumulation of tet-
SCLC cells H460 and H322 and the EsC cells TE2 and
er 12 or 24 hours and then harvested at 48 hours for
ssay and flow cytometry. Data are presented as means
tudent t test between 12-hour and 24-hour treatment
-Kramer multiple comparison tests between TSA of 1,he N
eith
rdU a
46, S
ukeyraploid (G2/M) cells, a concomitant reduction of cells in the
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TSFigure 3. A, Profound inhibition of TSA-mediated upregulation of p21 promotor activity and NF-B transcriptional
activity by the PKC inhibitor CC in all NSCLC and EsC cells. Data are presented as folds of increase of luciferase
activity over activity of untreated control cells (means  SEM of 4 independent experiments). B, Inhibition of
TSA-mediated upregulation of p21 levels by the PKC inhibitor CC. Protein levels of p21 in lysates of treated cells
were quantitated by means of enzyme-linked immunosorbent assay. The levels were normalized for total cellular
protein and then expressed as fold changes over levels of untreated control cells. Data are presented as means
 SEM of 4 independent experiments.
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antiapoptotic, and NF-B–dependent proteins. Increased induction of antiapoptotic proteins is seen in treatment
with TSA alone and in the proapoptotic protein, with little to no change in the combination treatment. However,
abrogation of the antiapoptotic proteins is seen in the TSACC combination. Representative data from 2
independent experiments with comparable results are shown.Figure 5. A, Synergistic inhibition of cell proliferation by the TSACC combinations in representative NSCLC H322
cells and EsC TE12 cells. Cells were treated with TSA (0.1-5.0 mol/L) for 12 hours, followed by a replacement with
drug-free culture media (TSA treatment alone) or culture media containing CC (0.25, 0.5, and 1.0 mol/L; TSACC
combinations). B, The TSACC combination effect was also examined in primary human fibroblasts and human
umbilical vein endothelial cells, respectively. Cell viability was determined by using the MTT assay 60 hours after
completion of TSA treatment. Dose-response curves of cells treated with the TSACC combinations were
constructed by normalizing for the mild growth-inhibitory effect of CC treatment alone. Data are presented as
means  SEM of 4 independent experiments.
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populations (Figure 1, B). TSA-mediated induction of apo-
ptosis was dependent on cell lines, the drug concentrations,
and the duration of drug exposure (Figure 2). For instance,
significant apoptosis was only observed in H322 and H460
cells after 24 hours of TSA exposure (P  .004 to .046,
Student t test between 12-hour and 24-hour treatment
groups). TSA-mediated dose-dependent induction of apo-
ptosis was observed in all cell lines, particularly in TE2 and
TE12 EsC cells, after either 12 or 24 hours of drug exposure
(P  .0079 to .013, analysis of variance with the Tukey-
Kramer pairwise comparison between TSA of 1, 2, and 5
mol/L and TSA of 0.5 mol/L).
Abrogation of TSA-Mediated Activation of NF-B and
p21 Promotor Transcriptional Activity by the PKC
Inhibitor CC
Exposure of EsC and NSCLC cells to TSA (1.0 mol/L for 6,
12, 18, or 24 hours) resulted in a treatment duration–dependent
5-fold to 30-fold upregulation of the p21 promotor and NF-B
transcriptional activity that reached a plateau at 18 and 24
hours (data not shown). Subsequent transcriptional studies
were performed with a 24-hour TSA treatment schedule. The
robust TSA-mediated activation of either the p21 promotor
activity or the NF-B transcriptional activity was totally abro-
gated by coexposure of treated cells to the PKC inhibitor CC
(Figure 3, A). In direct correlation with the p21 promotor
activity assay, the TSA-mediated increase of p21 protein ex-
pression, as determined by enzyme-linked immunosorbent as-
say, was significantly suppressed by CC cotreatment (Figure 3,
B). Similarly, upregulation of NF-B transcriptional activity
by TSA was paralleled by an increased expression of the
NF-B–dependent genes, such as those of the antiapoptotic
protein family cIAP-1, cIAP-2, and Bcl-XL (Figure 4). TSA-
mediated upregulation of these gene expressions was signifi-
cantly abrogated by the PKC inhibitor CC. Moreover, in-
creased expression of the antiapoptotic mcl-1 protein (not
currently known to be NF-B dependent) after TSA treatment
was also strongly inhibited by CC. On the other hand, levels of
the proapoptotic protein Bax were not altered significantly by
TSA, CC, or TSACC treatments. Taken together, there is a
substantial increase of the proapoptotic versus antiapoptotic
protein ratio, thus creating a proapoptotic milieu in cells treated
with the TSACC combination.
Enhancement of TSA-Mediated Cytotoxicity and
Apoptosis by the PKC Inhibitor CC
Subsequent exposure of TSA-treated cancer cells to differ-
ent concentrations of CC resulted in a significant further
reduction in cell viability compared with that seen with TSA
treatment alone. This is best demonstrated by dose-response
curves, where the viability of cells treated with the TSA and
CC combination were normalized for the mild growth-
inhibitory effect of CC (Figure 5, A), and of note, the
The Journal of ThoracTSACC drug combination was not toxic to primary nor-
mal cells (Figure 5, B). More importantly, although less than
15% of lung or EsC cells treated with either TSA alone or
CC alone underwent apoptosis, 80% to 96% of them were
TUNEL-positive within 48 hours of exposure to the
TSACC sequential combination, creating a profound syn-
ergistic cytocidal drug combination (Figure 6).
Enhancement of TSA-Mediated Apoptosis by NF-B
Inhibitor
NF-B transcriptional activity was suppressed with either a
pharmacologic inhibitor, parthenolide, or by overexpression
of the superrepressor IB (SR-IB, kinase-resistant mutant
of IB) by means of adenovirally mediated gene transfer
(AdV-SR-IB) to further elucidate the role of NF-B in
regulating p21 gene expression and apoptosis in TSA-
treated cells. Parthenolide (20 mol/L) or AdV-SR-IB
(200 pfu/cell), as predicted, completely suppressed TSA-
mediated NF-B transcriptional activation. These NF-B
inhibitors, however, also dramatically reduced TSA-in-
duced upregulation of the p21 promotor transcriptional ac-
tivity, implying that NF-B might play a role as an upstream
regulator of p21 gene expression (Figure 7, A). More im-
portantly, NF-B activation associated with TSA treatment
negatively influences the ability of this HDAC inhibitor to
induce cell death because profound induction of apoptosis
was observed in TSA-treated H322 or TE12 cells previously
infected with AdV-SR-IB (Figure 7, B).
Discussion
TSA, similar to other HDAC inhibitors, induces profound
Figure 6. Profound induction of apoptosis of NSCLC H322 and
H460 cells or EsC TE2 and TE12 cells by the combinations of TSA
and CC. Cells were treated with TSA alone (1.0 mol/L for 12
hours), CC alone (1.0 mol/L continuous exposure), or TSA fol-
lowed by continuous CC. Cells were harvested at 48 hours after
the onset of treatment to assay for apoptosis. Data are presented
as means  SEM of 4 independent experiments.dose-dependent cytoxicity in cancer cells. At lower con-
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arresting cells at the G0/G1 and G2/M checkpoints. Sub-
stantial apoptosis, on the other hand, is only observed
after prolonged treatment of cultured lung or EsC cells
with high concentrations of TSA. These conditions might
not be clinically achievable without significant systemic
toxicity. The phase I clinical trial of suberoylanilide
hydroxamic acid (an analog of TSA) indicated that the
maximally tolerated dose was 300 mg/m2 per day on a
schedule of 5 days per week for 3 weeks. Severe leuko-
penia and thrombocytopenia constituted the dose-limiting
toxicity in this study. The plasma suberoylanilide hy-
droxamic acid maximum concentration was approxi-
mately 9.0 mol/L, with a half-life of 60 minutes, result-
ing in an area under the curve of about 13.0 mol/L per
hour. Minor response was observed in 4 patients (4/29
[14%]).21 The in vitro TSA treatment conditions that
produced significant apoptosis in NSCLC and EsC cells
in our experiments would require an estimated area under
the curve of 24 or 60.0 mol/L per hour (1.0 or 5.0
mol/L per 24 hours of drug exposure). To enhance the
clinical utility of HDAC inhibitorbased therapy for
cancers, one needs to develop novel strategies to poten-
tiate the antitumor effect of HDAC inhibitor while keep-
ing dosing concentrations well within safe levels.
Both induction of p21 expression and increase of
NF-B transcriptional activity and expression of NF-B–
dependent genes are frequently observed in many cul-
tured cancer cell lines treated with HDAC inhibitor.
However, a common entity unifying these 2 potent anti-
apoptotic factors has not been elucidated. The NF-B
transcriptional factor is involved in multiple pathways
and can provide protection to cancer cells against apop-
tosis.14 The cdk inhibitor p21 is classically known to
mediate cell arrest and, as recently described, can exert
direct antiapoptotic effects,15 and multiple lines of evi-
dence have shown that HDAC inhibitor-mediated up-
regulation of p21 expression, NF-B transcriptional ac-
tivity, or both, actually inhibits drug-induced apoptosis.
More importantly, studies have conclusively shown that
PKC transcriptionally regulates p21 expression in HDAC
Figure 7. A, Selective inhibition of NF-B transcrip
(AdV-SR-IB) or the pharmacologic NF-B inhibitor
TSA-mediated NF-B activation but also the TSA-me
transiently transfected with either the NF-B–lucifera
further treatment with AdV-SR-IB (200 pfu/cell), parth
presented as folds of increase of luciferase activity o
independent experiments). B, Induction of apoptosis of
tion with TSA. Both AdV-SR-IB–infected cells and ve
hours) and harvested 12 hours later for quantitation
Representative data of 3 independent experiments are
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™inhibitor–treated cells16,22 and in other experimental condi-
The Journal of Thoractions; NF-B activation is under the regulatory control of
certain PKC isoforms.20 PKC therefore appears to be a
common regulator of both NF-B and p21 transcriptional
activity. Inhibition of PKC activity would suppress HDAC
inhibitor–associated transcriptional activation of either p21,
NF-B, or both, and should theoretically augment drug-
induced apoptosis. Our data provide clear experimental
evidence to support this hypothesis. The PKC inhibitor CC
effectively abrogates TSA-induced activation of both p21
promotor activity and NF-B transcriptional activity. Sub-
stantial and synergistic induction of apoptosis was observed
in all cultured thoracic cancer cells after treatment with the
TSACC combination.
One addition to the existing body of literature is our
observation that direct inhibition of NF-B activity with
SR-IB leads to transcriptional inhibition of p21 expres-
sion. In keeping with previous observations, direct inhi-
bition of NF-B in TSA-treated NSCLC and EsC cells
resulted in robust induction of apoptosis.10 Knowing that
SR-IB also suppressed p21 expression in TSA-treated
cells, it is not clear whether the increased cell death after
Ad-SR-IB and TSA treatment is mediated by the inhi-
bition of NF-B, the reduction of p21, or both. Further
experiments are being performed to elucidate the molec-
ular basis of this synergistic interaction between PKC
inhibitor, NF-B inhibitor, and HADC inhibitor combi-
nations.
In conclusion, we describe a novel strategy developed to
enhance the cytotoxic effect of HDAC inhibitor by exposing
treated cells to a PKC inhibitor. The 2 drugs were brought
together on the basis of the understanding of their molecular
interactions and the potential for a synergistic cytotoxic
effect. We identified p21 and NF-B as exploitable factors
with a common target for the development of more effective
and clinically applicable HDAC inhibitor–based therapeu-
tics for malignant disease.
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Discussion
Dr Thomas A. D’Amico (Durham, NC). Just to clarify, you did
demonstrate that Bcl-XL was downregulated, correct?
Dr Maxhimer. We saw that Bcl-XL was increased with HDAC
treatment, and then on addition of our PKC inhibitor, Bcl-XL was
downregulated.
Dr Yolonda Colson (Boston, Mass). What do you think are
potential mechanisms of resistance to these different pathways that
you are starting to block? Do you think that is going to be a
problem?
Dr Maxhimer. As far as we have seen, our results have been
consistent across cell lines. We have not looked at a meso cell line,
but we have looked at a wide array and also have started to use this
in an in vivo model. Our hope is that if this is going to be a
consistent downregulation of these resistant pathways, that we
will. We also want to use more clinically relevant drugs, HDAC
inhibitors as well as PKC inhibitors, to see this effect.
Dr Raphael Bueno (Boston, Mass). What happens to normal
cells when you do this?
Dr Maxhimer. Nothing. With the combination therapy, there is
no toxicity seen. If it gets further out, we see somewhat of a
reduction in cell viability. We also had some keratinocyte data and
the human umbilical vein endothelial cell lines that showed no
toxicity in these cell lines.
Dr Bueno. You flipped through that slide very fast. You
maintain that it is just the PKC inhibitor that downregulates the
various IAPs?
Dr Maxhimer. Yes.
Dr Bueno. And that alone does not cause increased apoptosis
in your cell lines?
Dr Maxhimer. I am sorry that I breezed through that too
quickly. In the next graph we saw little. We saw maybe 5% to 10%
with the PKC inhibitor alone that induces apoptosis, and it was in
comparison with the TSA, the HDAC inhibitor, but once we put
the 2 together, we saw a synergistic effect come together to see
90% to almost 100% induction of apoptosis.
Dr Bueno. Because I would wonder if you combined the PKC
inhibitor with other things without the deacetylase inhibitor
whether you actually need that because if you can alter the balance
of the antiapoptotic genes and the proapoptotic genes, you might
just be able to do with that. Have you tried to do that, the PKC
with, let us say, cisplatin?
Dr Maxhimer. That is actually a great question. No, we have
not looked at that, but we wanted to exploit some of the HDAC
qualities of cell growth inhibition and then use that to downregu-
late some of its other negative effects on resistance of apoptosis.
So that is kind of our scheme of why we are using these types of
treatments. But, no, we have not looked at PKC inhibition with
other combination therapies.
Dr Nguyen. I appreciate that question. I just want to clarify.
Work has been done before, not in our laboratory but actually at
ry 2005
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has been shown to enhance the chemotherapeutic effect. Therefore
it has been used as a target. Actually, PKC becomes a very
attractive target for drug development. The other issue is, with the
The Journal of Thoracadvent of RNA inhibitor, we can do these experiments very cleanly
by targeting Bcl-2 and Bcl-XL with a construct that basically
downregulates Bcl-2 or Bcl-XL, and we can hopefully see the
same results.
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